| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Nov 2026 | 5 Nov 2026 |
| Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a Meeting of the Board of Directors of Q-Line Biotech Limited (formerly known as Q-Line Biotech Private Limited) is scheduled to be held on Thursday, 12th Day of November, 2026 at 3:00 p.m. at the Registered Office of the Company inter alia, 1. To consider and approve the unaudited standalone and consolidated financial results, including the Statement of Assets and Liabilities, Cash Flow statement for the half year ended September 30, 2026, together with the Limited Review Reports issued by the Statutory Auditor. Q-Line Biotech Limited has informed the Exchange regarding Clarification-.that due to an inadvertent clerical error, the time in the subject line of the filing was mentioned as 3:00 P.M. instead of 4:15 P.M.We hereby clarify that the correct time of the Board Meeting is 4:15 P.M., as mentioned in the Board Meeting notice. The incorrect reference to 3:00 P.M. in the subject line may kindly be treated as an inadvertent error.We regret the inconvenience caused and request you to take the above clarification on record. (As Per NSE Announcement Dated On 05.11.2026) Q-Line Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. (As Per NSE Announcement Dated On : 12.11.2026) | ||
| Board Meeting | 5 Sep 2026 | 4 Sep 2026 |
| To consider other business matters Q-Line Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026. As Per Nse Announcement Dated On : 05.09.2026 | ||
| Board Meeting | 17 Jun 2026 | 12 Jun 2026 |
| inter alia, 1. To consider and approve the Standalone & Consolidated Audited Financial Results of the Company for the Financial Year ended 31st March, 2026 along with the Statement of Assets and Liabilities as on that date and Cash Flow Statement for the financial year ended 31st March, 2026 and to take on record Auditor s Report thereon by the Statutory Auditors of the Company.2. To Consider and Approve the Internal Audit Report of the Company.3. Any other business with permission of the Chair, if any. QLine Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. (As Per NSE Announcement Dated on : 17.06.2026) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.